
Chembio Diagnostics CEMI
Annual report 2022
added 03-29-2023
Chembio Diagnostics Interest Expense 2011-2026 | CEMI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 2.94 K | - | 836 | - | 335 | 9.5 K | 18.6 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.6 K | 335 | 6.45 K |
Quarterly Interest Expense Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.07 K | - | 3.85 K | 7.72 K | - | - | - | 1.31 K | - | - | 749 | - | - | - | - | - | - | - | - | - | 335 | - | 2.82 K | 2.32 K | 2.44 K | - | 4.87 K | 4.03 K | 4.44 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.72 K | 335 | 3.16 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 17.19 | - | $ 181 M | ||
|
CareDx, Inc
CDNA
|
524 K | $ 21.01 | 0.24 % | $ 1.12 B | ||
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
106 K | $ 1.57 | - | $ 2.09 M | ||
|
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
561 K | $ 14.66 | -3.04 % | $ 443 M | ||
|
Castle Biosciences
CSTL
|
1 K | $ 25.22 | -1.18 % | $ 701 M | ||
|
Agilent Technologies
A
|
81 M | $ 114.96 | 2.59 % | $ 34.9 B | ||
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M | ||
|
ICON Public Limited Company
ICLR
|
337 M | $ 112.87 | 0.8 % | $ 9.31 B | ||
|
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | ||
|
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | ||
|
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
31.3 M | $ 86.56 | -1.39 % | $ 5.84 B | ||
|
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-292 M | $ 138.5 | -0.63 % | $ 22 B | ||
|
Myriad Genetics
MYGN
|
800 K | $ 4.93 | -0.2 % | $ 457 M | ||
|
NeoGenomics
NEO
|
296 K | $ 8.85 | -1.67 % | $ 1.13 B | ||
|
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B | ||
|
National Research Corporation
NRC
|
-95 K | $ 18.73 | 2.8 % | $ 419 M | ||
|
Medpace Holdings
MEDP
|
-5.34 M | $ 415.65 | -0.33 % | $ 12 B | ||
|
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.49 | 0.95 % | $ 20 B | ||
|
Charles River Laboratories International
CRL
|
-22.6 M | $ 174.1 | 1.02 % | $ 8.63 B | ||
|
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
-10.5 M | $ 89.52 | -1.81 % | $ 11.2 B | ||
|
Personalis
PSNL
|
24 K | - | - | $ 350 M | ||
|
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | ||
|
Interpace Biosciences
IDXG
|
-252 K | $ 2.0 | -5.66 % | $ 8.85 M | ||
|
Thermo Fisher Scientific
TMO
|
-12 M | $ 464.17 | 0.35 % | $ 175 B | ||
|
Senseonics Holdings
SENS
|
-23 K | $ 4.9 | -2.2 % | $ 204 M | ||
|
Soleno Therapeutics
SLNO
|
110 K | $ 52.91 | 0.01 % | $ 2.69 B | ||
|
Twist Bioscience Corporation
TWST
|
-903 K | $ 58.58 | 4.25 % | $ 3.5 B | ||
|
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
367 | $ 2.17 | 0.46 % | $ 4.98 M | ||
|
Waters Corporation
WAT
|
14.3 M | $ 338.5 | 12.27 % | $ 20.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
224 M | $ 249.5 | -1.38 % | $ 20.8 B | ||
|
Celcuity
CELC
|
2.11 M | $ 142.8 | -1.5 % | $ 6.68 B | ||
|
Natera
NTRA
|
9.32 M | $ 207.48 | -1.93 % | $ 20.4 B | ||
|
Neogen Corporation
NEOG
|
38.1 M | $ 9.13 | 0.44 % | $ 1.98 B | ||
|
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | ||
|
Quest Diagnostics Incorporated
DGX
|
26 M | $ 190.66 | -0.48 % | $ 21.2 B |